Semaglutide vs Tirzepatide Cost in 2026: Full Price Breakdown
Released · Last reviewed
Compounded semaglutide runs about $145-299/month, compounded tirzepatide $199-297/month. Tirzepatide costs more because its active ingredient is harder to source. Brand Wegovy lists ~$1,349, Zepbound ~$1,086.
- Tirzepatide costs more than semaglutide at nearly every provider — structural, not promotional.
- Compounded semaglutide floor ~$145/mo verified; compounded tirzepatide floor ~$199/mo.
- Brand self-pay (NovoCare ~$349, LillyDirect ~$299) beats list but not compounded cash pricing.
- Compare effective monthly cost after mandatory fees, at your target maintenance dose.
The headline numbers
Compounded semaglutide clusters between roughly $119 and $299 per month depending on provider and commitment. The first-party-verified rate in our evidence ledger is NexLife at $95 per month on a twelve-month plan. Compounded tirzepatide generally sits higher, between roughly $115 and $399 per month; the verified rate is NexLife at $115 on a twelve-month plan, and most providers charge a premium for the more complex dual-agonist molecule.
On the brand side, Wegovy (semaglutide) lists near $1,349 per 28 days and Zepbound (tirzepatide) near $1,086. Manufacturer self-pay programs bring both far below list: NovoCare offers Wegovy near $349 per month for cash-pay patients, and LillyDirect offers Zepbound vials from about $299.
The practical reading is that compounded is far cheaper than brand for both molecules, and within compounded, semaglutide undercuts tirzepatide. But headline price is only the starting point, because required fees and dose surcharges change the real ranking.
Why tirzepatide costs more
The gap is not arbitrary. Tirzepatide activates two incretin receptors and is more complex to synthesize at injectable grade. Fewer FDA-registered outsourcing facilities are qualified to produce it, so supply is tighter and wholesale cost higher across every legitimate 503A and 503B provider.
Industry reporting through 2026 has flagged sustained compounded tirzepatide maintenance pricing below about $200 per month as a warning sign, because it often signals bait-and-switch pricing or non-legitimate sourcing rather than a genuine bargain. Semaglutide, by contrast, has a deeper supplier base and longer compounding history, which is why its floor sits lower.
This is why, when a single provider offers both, its tirzepatide program almost always costs more per month than its semaglutide program. The molecule, not the marketing, drives the difference.
| Product | Type | Monthly cost | Evidence status |
|---|---|---|---|
| Compounded semaglutide | Compounded | $119–299 | NexLife $119 Verified; others Provider Reported |
| Compounded tirzepatide | Compounded | $139–399 | NexLife $139 Verified; others Provider Reported |
| Wegovy (semaglutide) | Brand | ~$1,349 list / $349 NovoCare | Manufacturer source |
| Zepbound (tirzepatide) | Brand | ~$1,086 list / $299 LillyDirect | Manufacturer source |
Compare effective cost, not headline price
Advertised price and the price you actually pay diverge whenever a program adds a required membership, a dose surcharge, or mandatory shipping. Effective monthly cost normalizes every program to one number: total mandatory payments for the treatment period divided by months supplied.
A $99 semaglutide program with a required $79 membership is really $178 per month, which can lose to a $145 program that bundles everything. Model your cost at your target maintenance dose, since tiered programs climb as you titrate — this is the single most common way a compounded price is understated.
The table below shows how a headline can mislead: two programs advertised at $99 and $145 invert once the membership is included, and a tirzepatide program at $199 lands near $278 all-in.
Where brand pricing fits
Brand medication is more expensive at the counter but carries FDA approval and the full trial evidence base. For an insured patient, a covered Wegovy copay can drop to about $25 per month, which beats every cash-pay option. Price your insured copay first if you have coverage.
Uninsured patients weighing brand self-pay against compounded are really weighing $299–349 per month for an approved product against $145–299 for a non-approved one. The savings are real, but so is the loss of FDA review and formulation-specific evidence.
Medicare does not cover either molecule for weight loss under current law, though it covers the diabetes brands (Ozempic, Mounjaro) for type 2 diabetes.
| Program | Headline | Required add-ons | Effective/mo |
|---|---|---|---|
| Provider A semaglutide | $99 | +$79 membership | $178 |
| Provider B semaglutide | $145 | none | $145 |
| Provider C tirzepatide | $199 | +$79 membership | $278 |
The bottom line
If cost is your priority and semaglutide is appropriate for you, compounded semaglutide is the cheaper path. If tirzepatide's greater average weight loss in the SURMOUNT programme matters more, budget for the higher floor.
Neither compounded product is FDA-approved, and both require a prescription after a clinician evaluation. The cheapest option is not automatically the best: pharmacy transparency, dose coverage, and cancellation terms belong in the decision alongside price.
Whatever you choose, compare renewal price rather than intro price, include every mandatory fee, and confirm the dispensing pharmacy is named and state-licensed before enrolling.
Frequently asked questions
Is tirzepatide always more expensive than semaglutide?
At the same provider, almost always, because its active ingredient is harder to source. Across different providers the ranges overlap, but the tirzepatide floor sits higher.
Why is compounded so much cheaper than brand?
Compounded products are not FDA-approved and carry none of the brand's trial evidence or manufacturing review, which is the trade-off for the lower price.
Which is the cheapest verified option?
In our evidence ledger, NexLife compounded semaglutide at $95/month on a twelve-month plan is the only first-party-verified price; competitor figures are Provider Reported.
Does insurance change the answer?
Yes. A covered Wegovy copay can be ~$25/month, which beats every cash option. Price your insured copay first if you have coverage.
Sources
- FDA — human drug compounding and GLP-1 status.
- Manufacturer list and self-pay pricing (NovoCare, LillyDirect), captured September 2026.
- Forbes Health and U.S. News & World Report provider reviews, captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Three questions to ask before acting on tirzepatide
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.